| Anjan P Kaushik, | |
|
2200 Forest Ridge Pkwy, New Castle, IN 47362-2943 | |
| (765) 521-7385 | |
| Not Available |
| Full Name | Anjan P Kaushik |
|---|---|
| Gender | Male |
| Speciality | Hand Surgery |
| Experience | 15 Years |
| Location | 2200 Forest Ridge Pkwy, New Castle, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073757597 | NPI | - | NPPES |
| 201286900 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 01074873A (Indiana) | Secondary |
| 207XS0106X | Orthopaedic Surgery - Hand Surgery | 01074873A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Henry County Memorial Hospital | New castle, IN | Hospital |
| Reid Hospital & Health Care Services | Richmond, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Henry County Memorial Hospital | 6002724085 | 112 |
| New Castle Clinic Inc | 3274528757 | 37 |
News Archive
A Brazilian study shows that inhibition of an RNA named RMEL3, which is encoded by a previously uncharacterized gene (also named RMEL3), can reduce the viability of cultured melanoma cells by up to 95%.
Alize Pharma, a company specialized in the development of drugs for the treatment of metabolic diseases and rare diseases, announces today the launch of the first Phase I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2 diabetes.
Getting six to nine hours of sleep per night is associated with higher ratings for quality of life and lower ratings for depression, suggests a research abstract that will be presented Tuesday, June 14, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC.
Sinapis Pharma, Inc. announces that its first patients were dosed in a Phase I clinical trial study on June 14, 2010. This study, in human volunteers, is designed to evaluate the safety, pharmacokinetics, and absolute bioavailability of an intravenous infusion of methamphetamine. The first cohort, investigating shorter infusion times, went well. Future cohorts will evaluate longer infusion times and higher drug doses.
› Verified 9 days ago
| Entity Name | Henry County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891570537 PECOS PAC ID: 6002724085 Enrollment ID: O20031121000221 |
News Archive
A Brazilian study shows that inhibition of an RNA named RMEL3, which is encoded by a previously uncharacterized gene (also named RMEL3), can reduce the viability of cultured melanoma cells by up to 95%.
Alize Pharma, a company specialized in the development of drugs for the treatment of metabolic diseases and rare diseases, announces today the launch of the first Phase I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2 diabetes.
Getting six to nine hours of sleep per night is associated with higher ratings for quality of life and lower ratings for depression, suggests a research abstract that will be presented Tuesday, June 14, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC.
Sinapis Pharma, Inc. announces that its first patients were dosed in a Phase I clinical trial study on June 14, 2010. This study, in human volunteers, is designed to evaluate the safety, pharmacokinetics, and absolute bioavailability of an intravenous infusion of methamphetamine. The first cohort, investigating shorter infusion times, went well. Future cohorts will evaluate longer infusion times and higher drug doses.
› Verified 9 days ago
| Entity Name | New Castle Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801964960 PECOS PAC ID: 3274528757 Enrollment ID: O20041111000692 |
News Archive
A Brazilian study shows that inhibition of an RNA named RMEL3, which is encoded by a previously uncharacterized gene (also named RMEL3), can reduce the viability of cultured melanoma cells by up to 95%.
Alize Pharma, a company specialized in the development of drugs for the treatment of metabolic diseases and rare diseases, announces today the launch of the first Phase I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2 diabetes.
Getting six to nine hours of sleep per night is associated with higher ratings for quality of life and lower ratings for depression, suggests a research abstract that will be presented Tuesday, June 14, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC.
Sinapis Pharma, Inc. announces that its first patients were dosed in a Phase I clinical trial study on June 14, 2010. This study, in human volunteers, is designed to evaluate the safety, pharmacokinetics, and absolute bioavailability of an intravenous infusion of methamphetamine. The first cohort, investigating shorter infusion times, went well. Future cohorts will evaluate longer infusion times and higher drug doses.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anjan P Kaushik, Po Box 530, New Castle, IN 47362-0530 Ph: () - | Anjan P Kaushik, 2200 Forest Ridge Pkwy, New Castle, IN 47362-2943 Ph: (765) 521-7385 |
News Archive
A Brazilian study shows that inhibition of an RNA named RMEL3, which is encoded by a previously uncharacterized gene (also named RMEL3), can reduce the viability of cultured melanoma cells by up to 95%.
Alize Pharma, a company specialized in the development of drugs for the treatment of metabolic diseases and rare diseases, announces today the launch of the first Phase I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2 diabetes.
Getting six to nine hours of sleep per night is associated with higher ratings for quality of life and lower ratings for depression, suggests a research abstract that will be presented Tuesday, June 14, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC.
Sinapis Pharma, Inc. announces that its first patients were dosed in a Phase I clinical trial study on June 14, 2010. This study, in human volunteers, is designed to evaluate the safety, pharmacokinetics, and absolute bioavailability of an intravenous infusion of methamphetamine. The first cohort, investigating shorter infusion times, went well. Future cohorts will evaluate longer infusion times and higher drug doses.
› Verified 9 days ago
Clayton Edward Strong, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Forest Ridge Pkwy, Suite 240, New Castle, IN 47362 Phone: 765-521-7385 Fax: 765-521-7394 | |
Dr. Kyle William Siewert, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Forest Ridge Pkwy, Suite 240, New Castle, IN 47362 Phone: 765-521-7385 Fax: 765-521-7394 | |
Dr. Lindsey R Rolston, M.D Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Forest Ridge Pkwy, Suite #240, New Castle, IN 47362 Phone: 765-521-7385 Fax: 765-521-7394 | |
Dr. Thomas J. Mathews, M.D Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Forest Ridge Pkwy, Suite #240, New Castle, IN 47362 Phone: 765-521-7385 Fax: 765-521-7394 | |
Dr. Damion M. Harris, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Forest Ridge Pkwy, Suite #240, New Castle, IN 47362 Phone: 765-521-7385 Fax: 765-521-7394 |